Ariceum Therapeutics targeted radiopharmaceutical 177Lu-satoreotide exhibits promising clinical response and good tolerability profile in patients with advanced neuroendocrine tumours finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
1. Disease-free survival at 24 months was 84% in the nivolumab group compared to 73% in the observation group. 2. Grade 3-4 adverse events were more common in the nivolumab group, however, there were no reported deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: Merkel cell carcinoma (MCC), an aggressive skin cancer, poses a clinical
In this cohort study, researchers identified 6146 patients from 17 registries of the SEER Program who had been diagnosed with a first primary cutaneous Merkel cell carcinoma between 2000 and 2018.